Literature DB >> 17976856

Advancements in immune tolerance.

Ping-Ying Pan1, Junko Ozao, Zuping Zhou, Shu-Hsia Chen.   

Abstract

In recent years, considerable attention has been given to immune tolerance and its potential clinical applications for the treatment of cancers and autoimmune diseases, and the prevention of allo-graft rejection and graft-versus-host diseases. Advances in our understanding of the underlying mechanisms of establishment and maintenance of immune tolerance in various experimental settings and animal models, and in our ability to manipulate the development of various immune tolerogenic cells in vitro and in vivo, have generated significant momentum for the field of cell-based tolerogenic therapy. This review briefly summarizes the major tolerogenic cell populations and their mechanisms of action, while focusing mainly on potential exploitation of their tolerogenic mechanisms for clinical applications.

Entities:  

Mesh:

Year:  2007        PMID: 17976856      PMCID: PMC2228366          DOI: 10.1016/j.addr.2007.08.025

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  230 in total

Review 1.  Dendritic cells and the control of immunity.

Authors:  J Banchereau; R M Steinman
Journal:  Nature       Date:  1998-03-19       Impact factor: 49.962

Review 2.  Homeostasis and self-tolerance in the immune system: turning lymphocytes off.

Authors:  L Van Parijs; A K Abbas
Journal:  Science       Date:  1998-04-10       Impact factor: 47.728

3.  Myeloid differentiation treatment to diminish the presence of immune-suppressive CD34+ cells within human head and neck squamous cell carcinomas.

Authors:  M R Young; M A Wright; R Pandit
Journal:  J Immunol       Date:  1997-07-15       Impact factor: 5.422

Review 4.  Mouse CD1-specific NK1 T cells: development, specificity, and function.

Authors:  A Bendelac; M N Rivera; S H Park; J H Roark
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

5.  Association between alphabetaTCR+CD4-CD8- T-cell deficiency and IDDM in NOD/Lt mice.

Authors:  A G Baxter; S J Kinder; K J Hammond; R Scollay; D I Godfrey
Journal:  Diabetes       Date:  1997-04       Impact factor: 9.461

6.  Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span.

Authors:  C D Helgason; J E Damen; P Rosten; R Grewal; P Sorensen; S M Chappel; A Borowski; F Jirik; G Krystal; R K Humphries
Journal:  Genes Dev       Date:  1998-06-01       Impact factor: 11.361

7.  Induction of tolerance by IL-10-treated dendritic cells.

Authors:  K Steinbrink; M Wölfl; H Jonuleit; J Knop; A H Enk
Journal:  J Immunol       Date:  1997-11-15       Impact factor: 5.422

8.  Factors involved in the differentiation of TGF-beta-producing cells from naive CD4+ T cells: IL-4 and IFN-gamma have opposing effects, while TGF-beta positively regulates its own production.

Authors:  R A Seder; T Marth; M C Sieve; W Strober; J J Letterio; A B Roberts; B Kelsall
Journal:  J Immunol       Date:  1998-06-15       Impact factor: 5.422

9.  A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis.

Authors:  H Groux; A O'Garra; M Bigler; M Rouleau; S Antonenko; J E de Vries; M G Roncarolo
Journal:  Nature       Date:  1997-10-16       Impact factor: 49.962

10.  alpha/beta-T cell receptor (TCR)+CD4-CD8- (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10.

Authors:  K J Hammond; L D Poulton; L J Palmisano; P A Silveira; D I Godfrey; A G Baxter
Journal:  J Exp Med       Date:  1998-04-06       Impact factor: 14.307

View more
  8 in total

1.  Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer.

Authors:  Lei Miao; Jingjing Li; Qi Liu; Richard Feng; Manisit Das; C Michael Lin; Tyler J Goodwin; Oleksandra Dorosheva; Rihe Liu; Leaf Huang
Journal:  ACS Nano       Date:  2017-08-28       Impact factor: 15.881

2.  Prolonged infection by Fonsecaea pedrosoi after antigenic co-stimulation at different sites in experimental murine chromoblastomycosis.

Authors:  Alexandre Paulo Machado; Maria Regina Regis Silva; Olga Fischman
Journal:  Virulence       Date:  2010 Jan-Feb       Impact factor: 5.882

3.  Pivotal role of pervasive neoplastic and stromal cells reprogramming in circulating tumor cells dissemination and metastatic colonization.

Authors:  Didier Meseure; Kinan Drak Alsibai; Andre Nicolas
Journal:  Cancer Microenviron       Date:  2014-12-19

4.  Curcumin Micelles Remodel Tumor Microenvironment and Enhance Vaccine Activity in an Advanced Melanoma Model.

Authors:  Yao Lu; Lei Miao; Yuhua Wang; Zhenghong Xu; Yi Zhao; Youqing Shen; Guangya Xiang; Leaf Huang
Journal:  Mol Ther       Date:  2015-09-03       Impact factor: 11.454

5.  Blocking HIF-1α following radiotherapy to prolong and enhance the immune effects of radiotherapy: a hypothesis.

Authors:  Luo Wei; Ge Wei; Song Jin; Chen Cong; Xu Huilin; Ming Pingpo
Journal:  Med Sci Monit       Date:  2014-10-31

6.  Developing Phytocompounds from Medicinal Plants as Immunomodulators.

Authors:  Chih-Chun Wen; Hui-Ming Chen; Ning-Sun Yang
Journal:  Adv Bot Res       Date:  2012-06-19       Impact factor: 2.175

7.  HisgAtlas 1.0: a human immunosuppression gene database.

Authors:  Yuan Liu; Mengqi He; Dan Wang; Lihong Diao; Jinying Liu; Li Tang; Shuzhen Guo; Fuchu He; Dong Li
Journal:  Database (Oxford)       Date:  2017-01-01       Impact factor: 3.451

Review 8.  Tolerogenic Dendritic Cells on Transplantation: Immunotherapy Based on Second Signal Blockage.

Authors:  Priscila de Matos Silva; Julia Bier; Lisiery Negrini Paiatto; Cassia Galdino Albuquerque; Caique Lopes Souza; Luis Gustavo Romani Fernandes; Wirla Maria da Silva Cunha Tamashiro; Patricia Ucelli Simioni
Journal:  J Immunol Res       Date:  2015-10-12       Impact factor: 4.818

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.